home / stock / bioaf / bioaf news

BIOAF News and Press, Bioasis Technologies Inc From 01/22/21

Stock Information
Company Name: Bioasis Technologies Inc
Stock Symbol: BIOAF
Market: OTC
Website: bioasis.us
Menu
BIOAF BIOAF Quote BIOAF Short BIOAF News BIOAF Articles BIOAF Message Board
Get BIOAF Alerts

News, Short Squeeze, Breakout and More Instantly...
BIOAF - Bioasis Announces Stock Option Grant

GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3™ platform technology for the delivery of therapeutics across the blood-brai...
BIOAF - Bioasis Announces Annual General Meeting Details

GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC –Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB...

BIOAF - Bioasis Announces Sale of Royalty Interest in Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group-Bioasis Strategic Alliance to XOMA Corporation

GUILFORD, Conn., Nov. 03, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC –Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB...

BIOAF - Xoma acquires royalty interest in lysosomal storage disorder enzymes developed under Chiesi-Bioasis alliance

XOMA (XOMA) has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies (BIOAF), associated with the advancement of the enzymes being investigated as potential treatments for four different lysosomal storage disorders ((LSD)) under Bioasis’ strategic all...
BIOAF - XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group-Bioasis Strategic Alliance

EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies Inc. (TSXV:BTI.V; OTCQB:BIOAF), associated with the advancement of the enzymes being investig...

BIOAF - Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020

GUILFORD, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform techn...

BIOAF - Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform tec...
BIOAF - Bioasis Announces Issuance of US Patent Relating to xB³(TM) Platform Technology for The Delivery of Therapeutic Agents Across the Blood-Brain Barrier

GUILFORD, Conn., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3™ platform technology for th...

BIOAF - Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending May 31, 2020

BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central ner...

BIOAF - Bioasis and Chiesi Group to Host Webcast on July 16, 2020

BIOASIS TECHNOLOGIES INC . (“ Bioasis ”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“ BBB ”) and the t...
Previous 10 Next 10